🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06897293
Recruiting Observational

Comparison of MBR + Suture Tape and MBR for CLAI : A Prospective Cohort Study

NCT06897293 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Observational
Started
2021-06-01
Last updated
2026-05-20

Condition(s) studied

Ankle SprainHypermobility, Joint

Investigational drug(s) / intervention(s)

Modified Broström procedure + Suture tape augmentation operationModified Broström procedure operation

Modified Broström procedure + Suture tape augmentation operation: Patients with CLAI and GJL will accept the Modified Broström + Suture tape augmentation operation

Modified Broström procedure operation: Patients with CLAI and GJL will accept the Modified Broström procedure operation

Study summary

GJL is a risk factor for postoperative recurrent instability following an MBR for CLAI. Additional suture tape augmentation has been suggested to provide more strength and stability. However, the outcomes of the MBP with suture tape augmentation were unknown, which requires further exploration.

Eligibility

Sex
ALL
Min age
15 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: * Clinical diagnosis of lateral ankle instability * Beighton score ≥4 * Age with 18 to 60 years Exclusion Criteria: * Patients with an acute or subacute ankle injury * Injury of the deltoid ligament * Alignment of lower extremity greater than 5 degrees * Fractures of the lower extremity * Stage III or IV osteoarthritis * Patients who refused to participate in the study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University Third Hospital Beijing Beijing Municipality Recruiting

More Peking University Third Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06897293 on ClinicalTrials.gov ↗ ← All trials in China